Unique ID issued by UMIN | UMIN000049688 |
---|---|
Receipt number | R000056594 |
Scientific Title | Web-based questionnaire survey of physicians' practices and needs for an antiviral in patients with mild/moderate I COVID-19 without risk factors for disease progression |
Date of disclosure of the study information | 2022/12/06 |
Last modified on | 2023/03/28 15:07:30 |
Questionnaire survey about COVID-19 clinical practices and physicians' needs for an antiviral
Questionnaire survey about COVID-19 clinical practices and physicians' needs for an antiviral
Web-based questionnaire survey of physicians' practices and needs for an antiviral in patients with mild/moderate I COVID-19 without risk factors for disease progression
Questionnaire survey of physicians' practices and needs for antivirals in COVID-19 patients
Japan |
COVID-19
Infectious disease |
Others
NO
To evaluate the needs and impacts on clinical practice when an oral antiviral for these patients is available
Others
To confirm the current COVID-19 treatment and the burden on medical staff for mild/moderate I patients without risk factors
Others
Others
Not applicable
Impact on clinical practice when an oral antiviral is approved for mild/moderate I patients without risk factors
-Prescription intention of an antiviral and their reasons
-Expectation to an antiviral in those patient treatments
-Impacts on the burden of health care workers
Information on the care of mild/moderate I patients without risk factors
-Current practice of treatment, Satisfaction of treatment
-Degree of pressure on the medical system: Impact on other medical services, lack of personnel
-Burden on healthcare workers and their factors: working hours, infection control measures, and infection risk
-Impacts when healthcare workers infected
Observational
Not applicable |
Not applicable |
Male and Female
Persons who meet the following criteria in the screening survey
-Physician working in internal medicine or respiratory medicine
-Persons who have experience in the care of more than 20 mild/moderate I COVID-19 patients without risk factors from July to October 2022
Not applicable
400
1st name | Shinzo |
Middle name | |
Last name | Hiroi |
SHIONOGI & Co., Ltd.
Medical Affairs Department
561-0045
1-8, Doshomachi 3-chome, Chuo-ku, Osaka
080-2425-7440
shinzo.hiroi@shionogi.co.jp
1st name | Ippei |
Middle name | |
Last name | Morita |
SHIONOGI & Co., Ltd.
Medical Affairs Department
561-0045
1-8, Doshomachi 3-chome, Chuo-ku, Osaka
070-7812-7168
ippei.morita@shionogi.co.jp
SHIONOGI & Co., Ltd.
SHIONOGI & Co., Ltd.
Profit organization
Not applicable
Not applicable
-
-
NO
2022 | Year | 12 | Month | 06 | Day |
https://center6.umin.ac.jp/cgi-bin/ctr/ctr_file_dl.cgi?recptno=R000056594&file_id=00001&file_kind=1
Unpublished
464
Main treatment for mild patients without risk factors was "symptomatic treatment", and there was an intention to use antivirals in the hope of "prevention of severe illness" for moderate I patients. There are some patients who complain to their physicians about the lack of antivirals, while even if it becomes possible to prescribe, half of the respondents thought "no or little benefits for patients" or "no stress of healthcare providers is alleviated" and responded to not want to use them.
2023 | Year | 03 | Month | 28 | Day |
Completed
2022 | Year | 12 | Month | 12 | Day |
2023 | Year | 12 | Month | 13 | Day |
2022 | Year | 12 | Month | 13 | Day |
2023 | Year | 03 | Month | 31 | Day |
2023 | Year | 03 | Month | 31 | Day |
2023 | Year | 03 | Month | 31 | Day |
2023 | Year | 03 | Month | 31 | Day |
None
2022 | Year | 12 | Month | 05 | Day |
2023 | Year | 03 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056594
Research Plan | |
---|---|
Registered date | File name |
2022/12/13 | 医師ニーズ調査研究_実施計画書 Fix.pdf |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |